Academic Journal
Προβολή σε EDS

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.
Συγγραφείς: Stoppa A; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona., Fernández-Plaza T; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)., Giménez-Palomo A; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)., Pacchiarotti I; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Health Institute Carlos III (ISCIII).; Department of Medicine, School of Medicine and Health Sciences, Institute of Neurosciences (UBNeuro), University of Barcelona (UB)., Anmella G; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Health Institute Carlos III (ISCIII).; Department of Medicine, School of Medicine and Health Sciences, Institute of Neurosciences (UBNeuro), University of Barcelona (UB)., Fico G; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Health Institute Carlos III (ISCIII).; Department of Medicine, School of Medicine and Health Sciences, Institute of Neurosciences (UBNeuro), University of Barcelona (UB)., Sagué-Vilavella M; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona., Vázquez M; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona., Hidalgo-Mazzei D; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Health Institute Carlos III (ISCIII).; Department of Medicine, School of Medicine and Health Sciences, Institute of Neurosciences (UBNeuro), University of Barcelona (UB)., Pintor L; Department of Psychiatry and Psychology.; Consultation Liaison Psychiatry Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain., Vieta E; Department of Psychiatry and Psychology.; Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic of Barcelona.; Digital Innovation Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Health Institute Carlos III (ISCIII).; Department of Medicine, School of Medicine and Health Sciences, Institute of Neurosciences (UBNeuro), University of Barcelona (UB).
Πηγή: International clinical psychopharmacology [Int Clin Psychopharmacol] 2026 Nov 01; Vol. 41 (6), pp. 324-346. Date of Electronic Publication: 2026 Jun 11.
Τύπος έκδοσης: Systematic Review; Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 8609061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5857 (Electronic) Linking ISSN: 02681315 NLM ISO Abbreviation: Int Clin Psychopharmacol Subsets: MEDLINE
Imprint Name(s): Publication: London : Lippincott Williams And Wilkins
Original Publication: London : Clinical Neuroscience Publishers, c1986-
Ιατρικοί όροι (MeSH): Levetiracetam*/adverse effects , Anticonvulsants*/adverse effects , Bipolar Disorder*/chemically induced , Mania*/chemically induced , Psychoses, Substance-Induced*/etiology , Psychotic Disorders*/etiology, Humans ; Case Reports as Topic
Περίληψη: Levetiracetam (LEV) is a widely used antiepileptic but associated with psychiatric side effects. While mild reactions are common, manic and psychotic episodes are less frequent, though clinically significant. This review critically assesses published cases of (hypo)manic and psychotic episodes related to LEV. A systematic review was conducted using MEDLINE (PubMed), Cochrane Library, and Web of Science (up to 1 June 2025), restricted to studies with primary clinical data on (hypo)manic or psychotic episodes associated with LEV. The quality of each case was assessed using a critical appraisal checklist, and the Naranjo Adverse Drug Reaction Probability Scale was applied to evaluate causality. A total of 50 cases met the inclusion criteria: Eight (hypo)manic and 42 psychotic episodes. The most frequent psychiatric manifestations were delusions (48%), aggressiveness (44%), and manic symptoms (38%). Temporal lobe epilepsy was present in 26% of patients, and 66% had uncontrolled seizures. Although case reports describe an association between LEV and (hypo)manic and psychotic episodes, causality assessment based on the methodological approach applied indicated a low probability that LEV alone was responsible. Alternative explanations, including epilepsy-related factors and comorbid medical conditions, were frequently cited. In some cases, an alternative diagnosis might be manic episode with psychotic features .
(Copyright © 2026 Wolters Kluwer Health, LLC. All rights reserved.)
References: Abraham DS, Nguyen TPP, Blank LJ, Thibault D, Gray SL, Hennessy S, et al. (2023). Channeling of new neuropsychiatric drugs – impact on safety and effectiveness studies. Neurotherapeutics 20:375–388.
Aggarwal A, Sharma DD, Sharma RC, Kumar R (2011). Probable psychosis associated with levetiracetam: a case report. J Neuropsychiatry Clin Neurosci 23:E19–E20.
Akbari M, Jamshidi S, Sheikhi S, Alijani F, Kafshchi P, Taylor D (2024). Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: a systematic review of case reports. Psychopharmacology (Berl) 241:209–223.
Allard J, Henley W, McLean B, Watkins L, Parrett M, Rajakulendran S, et al. (2025). Levetiracetam in epilepsy and autism spectrum disorder: analysis of safety, tolerability, and efficacy. Epilepsy Behav 172:110678.
Altinöz AE, Tosun Altinöz S, Güzel Biltekin B, Can Kaya M (2019). Levetiracetam induced hypomania: a case report. Ther Adv Drug Saf 10:2042098619876754.
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Association.
Andrade DM (2022). Genetic mechanisms behind severe psychotic reactions to levetiracetam. Epilepsy Curr 23:29–31.
Bayerlein K, Frieling H, Beyer B, Kornhuber J, Bleich S (2004). Drug-induced psychosis after long-term treatment with levetiracetam. Can J Psychiatry 49:868.
Ben-Menachem E, Gilland E (2003). Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12:131–135.
Betts T, Waegemans T, Crawford P (2000). A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9:80–87.
Bhardwaj R, Singh G (2010). Levetiracetam-induced psychosis. Epilepsy Behav 17:614.
Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S (2002). Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 48:77–89.
Bräunig P, Krüger S (2003). Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 17:239–241.
de Bruijn MAAM, Van Sonderen A, Van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. (2019). Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92:e2185–e2196.
Bui M, Baslet G, Weisholtz D, McElrath T (2014). Levetiracetam-induced psychosis in a pregnant woman with prior substance abuse. Harv Rev Psychiatry 22:193–200.
Calle-López Y, Ladino LD, Benjumea-Cuartas V, Castrillón-Velilla DM, Téllez-Zenteno JF, Wolf P (2019). Forced normalization: a systematic review. Epilepsia 60:1610–1618.
Campbell C, McCormack M, Patel S, Stapleton C, Bobbili D, Krause R, et al.; EpiPGX Consortium (2022). A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia 63:1563–1570.
Celdran de Castro A, Nascimento FA, Beltran-Corbellini A, Toledano R, Garcia-Morales I, Gil-Nagel A, Aledo-Serrano A (2023). Levetiracetam, from broad-spectrum use to precision prescription: a narrative review and expert opinion. Seizure 107:121–131.
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I (2000). Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55:236–242.
Chen Z, Lusicic A, O’Brien T, Velakoulis D, Adams S, Kwan P (2016). Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain 139:2668–2678.
Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K (2017). Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76:24–31.
Chen D, Bian H, Zhang L (2019). A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy. Neuropsychiatr Dis Treat 15:905–917.
Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR (2014). The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 14:75.
Commission on Classification and Terminology of the International League Against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.
Cramer JA, Arrigo C, Van Hammée G, Gauer LJ, Cereghino JJ (2000). Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 41:868–874.
Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR (2003). A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 4:124–132.
Dannaram S, Borra D, Pulluri M, Jindal P, Sharma A (2012). Levetiracetam-induced acute psychotic episode. Innov Clin Neurosci 9:10–12.
Daryani KK, Bokade NK, Raichandani OP, Pandey SP (2014). Comparative study of efficacy, safety and tolerability of lamotrigine versus levetiracetam in the continuous maintenance phase of patients with bipolar depressive disorder. Int J Pharm Sci Rev Res 27:58–62.
Desarkar P, Das B, Sinha VK (2007). Adjuvant levetiracetam in adolescent mania. J Clin Psychopharmacol 27:215–216.
Devinsky O, Abramson H, Alper K, FitzGerald LS, Perrine K, Calderon J, Luciano D (1995). Postictal psychosis: a case control series of 20 patients and 150 controls. Epilepsy Res 20:247–253.
Dhungel O, Shrestha A, Pathak P, Sharma P (2023). Levetiracetam-induced acute psychosis in an adolescent. Case Rep Psychiatry 2023:5575900.
Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE (2003). Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: Report of 33 mild to severe cases. Epilepsy Behav 4:537–547.
Ekinci N, Güneş S, Ekinci O, Kalinli M, Okuyaz C, Direk MC (2019). Levetiracetam-related mania-like symptoms: an adolescent case. Clin Neuropharmacol 42:97–98.
Erdogan S, Aslan S, Yüksel N (2009). Psychotic disorder related to levetiracetam usage: report of two cases. Bulletin of Clinical Psychopharmacology 19:420–422.
Esang M, Kotapati P, Ahmed S (2018). Phenytoin augmentation of levetiracetam treatment: a case of forced normalization with emergence of psychosis. Cureus 10:e2432.
Esang M, Santos MG, Ahmed AS (2020). Levetiracetam and suicidality: a case report and literature review. Prim Care Companion CNS Disord 22:19nr02502.
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. (2017). Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 58:522–530.
Fonseca JB, Rodrigues R, Lourenço E, Morgado P (2020). Levetiracetam induced mania – A case report. Rev Psiquiatr Clín 47:30.
Freund BE, Jaeckle K, Quinones-Hinojosa A, Feyissa AM (2023). Case report: ‘aggressive’ perioperative antiseizure medication prophylaxis in patients with glioma-related epilepsy at high risk of early postoperative seizures following awake craniotomy. Front Surg 10:1282013.
Goldberg JF, Burdick KE (2002). Levetiracetam for acute mania. Am J Psychiatry 159:148.
Goldberg-Stern H, Feldman L, Eidlitz-Markus T, Kramer U, Perez S, Pollak L, Phatal-Valevski A (2013). Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram – a pilot study. Eur J Paediatr Neurol 17:248–253.
Grunze H, Langosch J, Born C, Schaub G, Walden J (2003). Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 64:781–784.
Gui J, Wang L, Meng L, Zhang X, Ma J, Jiang L (2025). Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database. Acta epileptologica 7:7.
Halma E, De Louw AJA, Klinkenberg S, Aldenkamp AP, Ijff DM, Majoie M (2014). Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure 23:685–691.
Hamed SA, Attiah FA (2019). Psychosis in adults with epilepsy and its relationship to demographic, clinical and treatment variables. Neurol Res 41:959–966.
Hernández JF, Moreno JC, Giraldo Urrea JN, Durán JP, Ramírez S (2017). Levetiracetam-induced psychosis in a patient with epilepsy. J Psychiatry 20:422.
Husum H, Bolwig TG, Sánchez C, Mathé AA, Hansen SL (2004). Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: Implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 5:204–215.
Isidoro MFF, Ong MT, Renato SD Jr (2023). Levetiracetam-induced psychosis in a Filipino female diagnosed with anti-N-methyl-D-aspartate receptor encephalitis: a case report. Int J Res Med Sci 11:3030–3033.
Jalihal V, Shankar R, Henley W, Parrett M, Tittensor P, McLean BN, et al. (2018). Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav 80:365–369.
Joanna Briggs Institute (2017). Checklist for case reports. https://jbi.global/critical-appraisal-tools . [Accessed 15 May 2026].
Josephson CB, Engbers JDT, Jette N, Patten SB, Singh S, Sajobi TT, et al. (2019). Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurol 76:440–446.
Kang BS, Moon HJ, Kim YS, Lee ST, Jung KH, Chu K, Lee SK (2013). The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord 15:302–310.
Kanner AM, Bicchi MM (2022). Antiseizure medications for adults with epilepsy: a review. JAMA 327:1269–1281.
Kanner AM, Rivas-Grajales AM (2016). Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. CNS Spectr 21:247–257.
Keshavarzi A, Sharifi A, Jahangard L, Soltanian A, Brühl AB, Ahmadpanah M, Brand S (2022). Levetiracetam as an adjunctive treatment for mania: a double-blind, randomized, placebo-controlled trial. Neuropsychobiology 81:192–203.
Kim SJH, Wood S, Marquina C, Foster E, Bell JS, Ilomäki J (2023). Shift from older- to newer-generation antiseizure medications in people with acute ischemic stroke in Australia: a population-based study. Epilepsia Open 8:1413–1424.
Kishi T, Hayakawa H, Kawamoto Y, Nakao Y, Narita T, Nishimoto K, et al. (2022). Levetiracetam for bipolar disorder: consideration from a systematic review. Bipolar Disord 24:834–835.
Kossoff EH, Bergey GK, Freeman JM, Vining EPG (2001). Levetiracetam psychosis in children with epilepsy. Epilepsia 42:1611–1613.
Krishnamoorthy ES, Trimble MR (1999). Forced normalization: clinical and therapeutic relevance. Epilepsia 40(Suppl 10):S57–S64.
Krüger S, Sarkar R, Pietsch R, Hasenclever D, Bräunig P (2008). Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania – a randomized open-label study. Psychopharmacology (Berl) 198:297–299.
Kumar N, Swaroop HS, Chakraborty A, Chandran S (2014). Levetiracetam induced acute reversible psychosis in a patient with uncontrolled seizures. Indian J Pharmacol 46:560–561.
Kyomen HH (2006). The use of levetiracetam to decrease mania in elderly bipolar patients. Am J Geriatr Psychiatry 14:985.
Kyomen HH, Whitfield TH, Baldessarini RJ (2007). Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer’s type. J Clin Psychopharmacol 27:408–410.
Lalli M, Brouillette K, Kapczinski F, de Azevedo Cardoso T (2021). Substance use as a risk factor for bipolar disorder: a systematic review. J Psychiatr Res 144:285–295.
Lamberty Y, Margineanu D, Klitgaard H (2001). Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2:454–459.
Landolt H (1953). Some clinical EEG correlations in epileptic psychoses (twilight states). Electroencephalogr Clin Neurophysiol 5:121.
León Ruiz M, Rodríguez Sarasa ML, Sanjuán Rodríguez L, Benito-León J, Álvarez de Toledo O, Pérez Nieves MT, Arce Arce S (2020). Levetiracetam-induced de novo psychosis: Is there a type of patient with epilepsy who is neurostructural and/or biologically more vulnerable to developing it? Neurologia 35:684–687.
Li AD, Loi SM, Velakoulis D, Walterfang M (2023). Mania following traumatic brain injury: a systematic review. J Neuropsychiatry Clin Neurosci 35:341–351.
Li J, Zhong R, Zhang F, Guo Y (2025). Psychiatric disorders associated with newer antiseizure medications: a real-world disproportionality analysis of FDA adverse event reporting system. Epilepsy Behav 172:110722.
Lin PC, Chen CY, Chu CW, Tai YM, Hueng DY, Tzeng NS (2019). Psychotic symptoms related to the prophylactic use of levetiracetam after brain surgery. Am J Ther 26:e767–e768.
Lo B, Kyu H, Jichici D, Upton A, Akl E, Meade M (2011). Meta-analysis of randomized trials on first line and adjunctive levetiracetam. Can J Neurol Sci 38:475–486.
Loganathan MA, Enja M, Lippmann S (2015). Forced normalization: epilepsy and psychosis interaction. Innov Clin Neurosci 12:38–41.
Logsdail SJ, Toone BK (1988). Post-ictal psychoses. A clinical and phenomenological description. Br J Psychiatry 152:246–252.
Madhusoodanan S, Ting MB, Farah T, Ugur U (2015). Psychiatric aspects of brain tumors: a review. World J Psychiatry 5:273–285.
Majarwitz D, Dvalishvili M, Pastis I (2022). Levetiracetam-induced psychosis in the setting of intracranial cavernomas. Case Rep Psychiatry 2022:9114118.
Martins CP, Carvalho S, Correia AP, Pinto da Costa M (2020). Schizophrenia-like psychosis induced by levetiracetam in a patient with epilepsy. Actas Esp Psiquiatr 48:181–190.
Matheson SL, Laurie M, Laurens KR (2023). Substance use and psychotic-like experiences in young people: a systematic review and meta-analysis. Psychol Med 53:305–319.
Meyrel M, Veyrier M, Nieto I, Bellivier F, Geoffroy PA (2019). Two manic episodes related to a levetiracetam-based treatment in a 34-year-old female patient: a case report. J Clin Psychopharmacol 39:87–88.
Mirzazadeh H, Nourollahi M, Assadian K, Bordbar S, Jahromi LR, Moshfeghinia R (2025). Investigating the efficacy of levetiracetam as an adjunct to olanzapine for acute manic episodes of bipolar disorder: a double-blind placebo-controlled randomized clinical trial. J Affect Disord 387:119526.
Muhrer E, Moxam A, Dunn M, Rosen A, Taylor JH, Camacho P, et al. (2022). Acute medical workup for new-onset psychosis in children and adolescents: a retrospective cohort. J Hosp Med 17:907–911.
Mula M, Trimble MR, Yuen A, Liu RS, Sander JW (2003). Psychiatric adverse events during levetiracetam therapy. Neurology 61:704–706.
Mula M, Trimble MR, Sander JW (2007). Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 48:2322–2326.
Muralidharan A, Bhagwagar Z (2006). Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 20:969–979.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. (1981). A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245.
Nicolson A, Lewis SA, Smith DF (2004). A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 63:568–570.
Nishida T, Kudo T, Inoue Y, Nakamura F, Yoshimura M, Matsuda K, et al. (2006). Postictal mania versus postictal psychosis: differences in clinical features, epileptogenic zone, and brain functional changes during postictal period. Epilepsia 47:2104–2114.
Ogunsakin O, Tumenta T, Louis-Jean S, Mahbub A, Rabel P, Olupona T, Alam S (2020). Levetiracetam induced behavioral abnormalities in a patient with seizure disorder: a diagnostic challenge. Case Rep Psychiatry 2020:8883802.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016). Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210.
Ozcan H, Ulkevan T, Fatih Ustundag M, Yucel A (2015). Levetiracetam-induced acute mania. Klinik Psikofarmakol Bülteni 25:319–320.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71.
Park EM, Holmes JA, Reeder-Hayes KE (2014). Acute mania associated with levetiracetam treatment. Psychosomatics 55:98–100.
Park SJ, Lee HB, Ahn MH, Park S, Choi EJ, Lee HJ, et al. (2015). Identifying clinical correlates for suicide among epilepsy patients in South Korea: a case–control study. Epilepsia 56:1966–1972.
Patrizio E, Vezza C, Manzoni A, Clerici M, Mandelli C, Schinco GL, Cesari M (2018). Acute psychosis in a patient with metabolic disorder and receiving anti-epileptic therapy with levetiracetam. Geriatr Gerontol Int 18:1647–1648.
Pinckaers FME, Boon ME, Majoie MHJM (2019). Risk factors predisposing to psychotic symptoms during levetiracetam therapy: a retrospective study. Epilepsy Behav 100:106344.
Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, et al. (2005). Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 66:370–374.
Prasad Gajurel B, Kharel S, Bhagat R, Ghimire R, Bhusal K, Rijal D (2024). Anti-epileptic drugs use and increased risk of stroke: a systematic review. Ann Neurosci 31:283–291.
de Prisco M, Vieta E (2024). The never-ending problem: Sample size matters. Eur Neuropsychopharmacol 79:17–18.
Ramesan R, Swamy RS, Shashidhara HL, Pradeep N, Avinash KS, Kulkarni VG (2018). Acute psychosis associated with levetiracetam in a patient with frontal lobe tumour. J Med Sci Clin Res 6:484–486.
Regi A, Hussain A, Regi A, Davies B (2024). Levetiracetam induced acute reversible psychosis: a case report. Ann Case Rep 10:2227.
Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, et al. (2013). A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 16:485–496.
Revdal E, Morken G, Bakken IJ, Bråthen G, Landmark CJ, Brodtkorb E (2022). Bidirectionality of antiseizure and antipsychotic treatment: a population-based study. Epilepsy Behav 136:108911.
Rizvi S, Farooq F, Shagufta S, Khan AM, Masood Y, Saeed H (2018). Postictal mania versus postictal psychosis. Cureus 10:e3338.
Rohde NN, Baca CB, Van Cott AC, Parko KL, Amuan ME, Pugh MJ (2015). Antiepileptic drug prescribing patterns in Iraq and Afghanistan war veterans with epilepsy. Epilepsy Behav 46:133–139.
Roig J, Carreño MM, Parellada E (2007). Probable levetiracetam-induced psychosis. Med Clin (Barc) 129:278.
Ropper AH, Espinoza RT, Kellner CH (2022). Electroconvulsive therapy. N Engl J Med 386:667–672.
Sanmugabatham S, Bastiampillai T, Dhillon R, Khan M (2009). Levetiracetam-induced psychosis. Aust N Z J Psychiatry 43:977–979.
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, et al. (2011). Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72:744–750.
Sarmast ST, Abdullahi AM, Jahan N (2020). Current classification of seizures and epilepsies: scope, limitations and recommendations for future action. Cureus 12:e10549.
Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P (2000). Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41:1179–1186.
Smith EG, Patel KM (2024). The role of case series and case reports in evidence-based medicine. J Clin Psychopharmacol 44:81–85.
Stangeland H, Orgeta V, Bell V (2018). Poststroke psychosis: a systematic review. J Neurol Neurosurg Psychiatry 89:879–885.
Starkstein SE, Boston JD, Robinson RG (1988). Mechanisms of mania after brain injury. 12 case reports and review of the literature. J Nerv Ment Dis 176:87–100.
Steinhoff BJ, Staack AM (2019). Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord 12:1756286419873518.
Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, et al. (2021). Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav 118:107939.
Stoppa A, Anmella G, Delgado L, Vallès V, Pintor L (2022). A manic episode with psychotic features associated with levetiracetam: a case report, a proposal of prodromal and discriminative symptoms and a possible pathophysiological mechanism. J Clin Psychopharmacol 42:316–317.
Taneja R, Hunter K, Burakgazi-Dalkilic E, Carran M (2017). Effect of sleep patterns on levetiracetam induced mood changes. Epilepsy Behav 75:237–240.
Tao K, Chen H, Chen Y, Gu Y, Wang X (2024). Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure 116:147–150.
Tarrada A, Hingray C, Aron O, Dupont S, Maillard L, de Toffol B (2022). Postictal psychosis, a cause of secondary affective psychosis: a clinical description study of 77 patients. Epilepsy Behav 127:108553.
Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S (2007). Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 48:2336–2344.
de Toffol B (2024). Epilepsy and psychosis. Rev Neurol (Paris) 180:298–307.
Topkan A, Bilen S, Titiz AP, Eruyar E, Ak F (2016). Forced normalization: an overlooked entity in epileptic patients. Asian J Psychiatr 23:93–94.
Trebbau-López H, Rodríguez-Toledo S, Reyes-Molón L, Del Río-Vega J (2012). Levetiracetam and psychosis. Actas Esp Psiquiatr 40:49.
Trimble MR (1996). Anticonvulsant-induced psychiatric disorders. The role of forced normalisation. Drug Saf 15:159–166.
Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ (2007). Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 10:105–110.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20:97–170.
Youroukos S, Lazopoulou D, Michelakou D, Karagianni J (2003). Acute psychosis associated with levetiracetam. Epileptic Disord 5:117–119.
Zaki SA, Gupta S (2014). Levetiracetam-induced acute psychosis in a child. Indian J Pharmacol 46:341–342.
Zarezadeh F, Arbabi M, Shamabadi A, Naderi S, Hasanzadeh A, Ostadpour M, et al. (2022). Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. Int Clin Psychopharmacol 37:46–53.
Zhao D, Shridharmurthy D, Alcusky MJ, Yuan Y, Nunes AP, Hume AL, et al. (2020). The prevalence and factors associated with antiepileptic drug use in US nursing home residents. Drugs Aging 37:137–145.
Contributed Indexing: Keywords: drug-related side effects and adverse reactions; epilepsy; levetiracetam; mania; psychotic disorder
Substance Nomenclature: 44YRR34555 (Levetiracetam)
0 (Anticonvulsants)
Entry Date(s): Date Created: 20260614 Date Completed: 20261006 Latest Revision: 20261006
Update Code: 20261006
DOI: 10.1097/YIC.0000000000000632
PMID: 42289003
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1473-5857
DOI:10.1097/YIC.0000000000000632